NUWE - Nuwellis, Inc. Stock Price, Fair Value and News

0.26USD-0.01 (-3.70%)Market Closed

Market Summary

USD0.26-0.01

Market Closed

-3.70%

NUWE Stock Price

View Fullscreen

NUWE RSI Chart

NUWE Valuation

Market Cap

4.7M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

0.53

EV/EBITDA

-0.19

Price/Free Cashflow

-0.32

NUWE Price/Sales (Trailing)

NUWE Profitability

EBT Margin

-202.88%

Return on Equity

-2.0K%

Return on Assets

-262.88%

Free Cashflow Yield

-316.58%

NUWE Fundamentals

NUWE Revenue

Revenue (TTM)

8.9M

Rev. Growth (Yr)

1.7%

Rev. Growth (Qtr)

-27.21%

NUWE Earnings

Earnings (TTM)

-17.5M

Earnings Growth (Yr)

41.57%

Earnings Growth (Qtr)

31.22%

Breaking Down NUWE Revenue

Last 7 days

Last 30 days

-7.1%

Last 90 days

-56.7%

Trailing 12 Months

-91.5%

How does NUWE drawdown profile look like?

NUWE Financial Health

Current Ratio

1.2

NUWE Investor Care

Shares Dilution (1Y)

1395.61%

Diluted EPS (TTM)

-6.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.9M	0	0	0
2023	8.4M	8.3M	8.7M	8.9M
2022	7.9M	7.6M	7.8M	8.5M
2021	7.7M	8.4M	8.3M	7.9M
2020	5.9M	6.1M	6.8M	7.4M
2019	5.2M	5.8M	5.6M	5.5M
2018	3.7M	3.9M	4.3M	5.0M
2017	2.2M	3.1M	3.5M	3.6M
2016	0	0	543.0K	1.3M
2015	295.0K	295.0K	236.0K	59.0K
2014	118.0K	177.0K	236.0K	295.0K
2013	0	0	233.0K	59.0K
2010	0	0	0	407.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nuwellis, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2023	jaramillo nestor jr.	bought	19,629	4.79	4,098	president and ceo

Which funds bought or sold NUWE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	24.83	-183	598	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	9,258	9,258	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-45.39	-8,390	4,211	-%
May 15, 2024	CITADEL ADVISORS LLC	added	492	29,857	41,063	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	-2.00	3.00	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-2,461	3,989	-%
May 13, 2024	FMR LLC	added	300	-	1.00	-%
May 13, 2024	UBS Group AG	new	-	168	168	-%
May 13, 2024	HRT FINANCIAL LP	new	-	4,000	4,000	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-32,000	-	-%

Are Funds Buying or Selling NUWE?

Are funds buying NUWE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NUWE

No. of Funds

Unveiling Nuwellis, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 06, 2024	s.h.n. financial investments ltd.	5.7%	1,041,668	SC 13G
May 03, 2024	intracoastal capital, llc	4.99%	815,023	SC 13G
Feb 13, 2023	lind global fund ii lp	0.2%	54,482	SC 13G/A
Oct 20, 2022	lind global fund ii lp	8.1%	2,550,000	SC 13G
Feb 08, 2022	hudson bay capital management lp	0%	0	SC 13G/A
Feb 03, 2022	bigger capital fund l p	1.6%	65,994	SC 13G/A

Recent SEC filings of Nuwellis, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	ARS	ARS
May 17, 2024	DEFR14A	DEFR14A
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	PRER14A	PRER14A
May 07, 2024	8-K	Current Report
May 06, 2024	SC 13G	Major Ownership Report
May 03, 2024	SC 13G	Major Ownership Report
May 01, 2024	DEF 14A	DEF 14A
May 01, 2024	8-K	Current Report
Apr 29, 2024	424B4	Prospectus Filed

Peers (Alternatives to Nuwellis, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Nuwellis, Inc. News

Latest updates

Nuwellis, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-27.2%	1,857,000	2,551,000	2,412,000	2,075,000	1,826,000	2,339,000	2,065,000	2,213,000	1,926,000	1,642,000	1,853,000	2,508,000	1,918,000	2,044,000	1,904,000	1,863,000	1,630,000	1,367,000	1,252,000	1,677,000	1,215,000
Gross Profit	-14.2%	1,191,000	1,388,000	1,381,000	1,147,000	1,067,000	1,331,000	1,259,000	1,063,000	1,102,000	894,000	1,120,000	1,511,000	966,000	1,146,000	878,000	1,199,000	834,000	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,328,500	6,161,000	5,783,000	6,197,000	5,813,000	5,759,000	6,105,000	5,940,000
Operating Expenses	19.3%	5,940,000	4,981,000	4,545,000	6,169,000	6,918,000	5,865,000	5,179,000	5,364,000	5,518,000	5,225,000	6,371,000	6,237,000	6,184,000	5,430,500	5,135,000	5,119,000	5,401,000	-	-	-	-
S&GA Expenses	27.6%	4,606,000	3,609,000	3,428,000	4,664,000	5,490,000	4,664,000	4,251,000	4,257,000	4,412,000	4,094,000	4,645,000	5,063,000	5,237,000	4,382,500	4,264,000	4,234,000	4,537,000	4,187,000	4,107,000	3,973,000	4,018,000
R&D Expenses	-2.8%	1,334,000	1,372,000	1,117,000	1,505,000	1,428,000	1,201,000	928,000	1,107,000	1,106,000	1,131,000	1,726,000	1,174,000	947,000	1,048,000	871,000	885,000	864,000	953,000	1,112,000	1,297,000	1,310,000
EBITDA Margin	11.1%	-1.99	-2.24	-1.88	-2.02	-1.92	-1.66	-2.11	-2.35	-2.31	-2.41	-2.14	-2.01	-	-	-	-	-	-	-	-	-
Income Taxes	0%	2,000	2,000	2,000	2,000	2,000	3,000	2,000	2,000	2,000	2,000	2,000	3,000	2,000	2,000	3,000	2,000	2,000	3,000	1,000	2,000	2,000
Earnings Before Taxes	21.4%	-4,328,000	-5,507,000	-3,368,000	-4,843,000	-6,483,000	-1,893,000	-3,868,000	-4,284,000	-4,471,000	-4,328,000	-5,270,000	-4,728,000	-5,219,000	-3,084,000	-4,257,000	-3,920,000	-4,566,000	-4,445,000	-4,508,000	-4,428,000	-4,725,000
EBT Margin	11.0%	-2.03	-2.28	-1.92	-2.06	-1.96	-1.70	-2.16	-2.40	-2.37	-2.47	-2.20	-2.06	-	-	-	-	-	-	-	-	-
Net Income	31.2%	-3,789,000	-5,509,000	-3,370,000	-4,845,000	-6,485,000	-1,896,000	-3,870,000	-4,286,000	-4,473,000	-4,330,000	-5,272,000	-4,731,000	-5,221,000	-3,086,000	-4,260,000	-3,922,000	-4,568,000	-4,448,000	-4,509,000	-4,430,000	-4,727,000
Net Income Margin	13.6%	-1.97	-2.28	-1.92	-2.06	-1.96	-1.70	-2.16	-2.41	-2.37	-2.47	-2.20	-2.07	-	-	-	-	-	-	-	-	-
Free Cashflow	-6.4%	-2,891,000	-2,718,000	-3,946,000	-5,303,000	-6,119,000	-3,146,000	-3,279,000	-3,949,000	-4,897,000	-4,183,000	-4,540,000	-3,901,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-31.8%	6,662	9,770	11,432	15,553	18,479	24,673	18,437	21,998	26,107	30,417	34,095	29,640	33,563	20,012	23,719	13,143	10,047	5,602	7,584	11,428	15,363
Current Assets	-36.7%	5,197	8,209	9,638	13,748	16,610	22,769	16,440	19,920	23,895	28,126	32,725	28,224	32,138	18,536	22,151	11,729	8,732	4,036	6,051	10,302	14,251
Cash Equivalents	-63.2%	1,400	3,800	4,930	8,896	11,515	17,737	12,053	15,345	19,300	8,742	28,431	23,978	27,893	14,437	17,947	7,821	5,669	1,279	3,634	7,402	11,489
Inventory	6.7%	2,131	1,997	2,336	2,733	2,742	2,661	2,919	3,010	3,294	2,843	2,805	2,656	2,957	2,957	2,921	2,789	2,195	1,797	1,612	1,690	1,790
Net PPE	-6.5%	681	728	912	875	907	980	1,027	1,063	1,153	1,188	1,265	1,260	1,219	1,200	1,244	1,042	897	991	1,025	574	518
Liabilities	-12.0%	5,775	6,559	3,593	4,479	4,815	12,316	4,421	4,334	4,394	4,470	4,114	3,644	3,211	3,694	3,391	3,541	2,343	3,612	3,246	2,994	2,835
Current Liabilities	36.3%	4,323	3,172	2,992	3,825	4,107	4,688	3,611	3,459	3,392	3,307	3,795	3,603	3,163	3,585	3,223	3,335	2,131	3,351	2,937	2,637	2,432
Shareholder's Equity	-70.4%	885	2,990	7,839	11,074	13,664	12,357	14,016	17,664	21,713	25,947	29,981	25,996	30,352	16,318	20,328	9,602	7,704	1,990	4,338	8,434	12,528
Retained Earnings	-1.5%	-291,956	-287,600	-282,100	-278,747	-273,900	-267,417	-265,545	-261,700	-257,389	-252,892	-257,400	-243,300	-238,559	-233,338	-230,252	-225,992	-222,070	-217,502	-213,054	-208,545	-204,115
Additional Paid-In Capital	0.8%	292,880	290,646	289,980	289,845	287,529	279,736	279,570	279,350	279,114	278,874	278,552	269,296	268,921	249,663	249,378	234,381	228,560	218,278	216,173	215,761	215,422
Shares Outstanding	19.7%	6,801	5,682	1,864	1,864	1,207	536	105	105	105	105	56.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5,000	-	-	-	6,200	-	-	-	27,400	-	-	-	8,300	-	-	-	8,300	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-3.9%	-2,862	-2,754	-3,825	-5,252	-6,106	-3,127	-3,257	-3,938	-4,827	-4,155	-4,486	-3,820	-5,382	-3,409	-4,403	-3,265	-5,495	-4,030	-3,463	-3,967	-4,907
Share Based Compensation	0.6%	158	157	135	197	181	165	220	236	241	321	257	381	355	313	309	347	380	399	412	339	362
Cashflow From Investing	-180.6%	-29.00	36.00	-121	513	-98.00	14,831	-22.00	-11.00	-70.00	-15,528	-54.00	-81.00	-56.00	-60.00	-138	-52.00	-17.00	-26.00	-306	-117	-41.00
Cashflow From Financing	-68.7%	500	1,595	-20.00	2,119	-11.00	9,451	-15.00	-7.00	-6.00	-5.00	8,993	-14.00	18,897	-34.00	14,674	5,471	9,905	1,706	-	-	10,959

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NUWE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 1,857	$ 1,826
Cost of goods sold	666	759
Gross profit	1,191	1,067
Operating expenses:
Selling, general and administrative	4,606	5,490
Research and development	1,334	1,428
Total operating expenses	5,940	6,918
Loss from operations	(4,749)	(5,851)
Other income (expense), net	(101)	123
Change in fair value of warrant liability	522	(755)
Loss before income taxes	(4,328)	(6,483)
Income tax expense	(2)	(2)
Net loss	(4,330)	(6,485)
Deemed dividend attributable to Series J Convertible Preferred Stock	541	0
Net loss attributable to common stockholders	$ (3,789)	$ (6,485)
Basic loss per share (in dollars per share)	$ (0.6)	$ (5.76)
Diluted loss per share (in dollars per share)	$ (0.6)	$ (5.76)
Weighted average shares outstanding - basic (in shares)	6,286,298	1,125,993
Weighted average shares outstanding - diluted (in shares)	6,286,298	1,125,993
Other comprehensive loss:
Net loss	$ (4,330)	$ (6,485)
Unrealized gain on marketable securities	0	6
Foreign currency translation adjustments	(9)	(7)
Total comprehensive loss	$ (4,339)	$ (6,486)

NUWE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 1,400	$ 3,800
Accounts receivable	1,226	1,951
Inventories, net	2,131	1,997
Other current assets	440	461
Total current assets	5,197	8,209
Property, plant and equipment, net	681	728
Operating lease right-of-use asset	664	713
Other assets	120	120
TOTAL ASSETS	6,662	9,770
Current liabilities
Accounts payable and accrued liabilities	3,332	2,380
Accrued compensation	725	525
Current portion of operating lease liability	221	216
Other current liabilities	45	51
Total current liabilities	4,323	3,172
Common stock warrant liability	964	2,843
Operating lease liability	488	544
Total liabilities	5,775	6,559
Commitments and contingencies
Mezzanine Equity
Series J Convertible Preferred Stock as of March 31, 2024 and December 31, 2023, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 82 and 11,950, respectively	2	221
Stockholders' equity
Preferred stock	0	0
Common stock as of March 31, 2024 and December 31, 2023, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 6,801,443 and 5,682,461, respectively	1	1
Additional paid-in capital	292,880	290,646
Accumulated other comprehensive income:
Foreign currency translation adjustment	(40)	(31)
Accumulated deficit	(291,956)	(287,626)
Total stockholders' equity	885	2,990
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	6,662	9,770
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	$ 0	$ 0

About Nuwellis, Inc.

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

CEO	Mr. Nestor Jaramillo Jr.
WEBSITE	nuwellis.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	70

Nuwellis, Inc. Frequently Asked Questions

What is the ticker symbol for Nuwellis, Inc.? What does NUWE stand for in stocks?

NUWE is the stock ticker symbol of Nuwellis, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuwellis, Inc. (NUWE)?

As of Fri May 17 2024, market cap of Nuwellis, Inc. is 4.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NUWE stock?

You can check NUWE's fair value in chart for subscribers.

What is the fair value of NUWE stock?

You can check NUWE's fair value in chart for subscribers. The fair value of Nuwellis, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nuwellis, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NUWE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nuwellis, Inc. a good stock to buy?

The fair value guage provides a quick view whether NUWE is over valued or under valued. Whether Nuwellis, Inc. is cheap or expensive depends on the assumptions which impact Nuwellis, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NUWE.

What is Nuwellis, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NUWE's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 0.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUWE PE ratio will change depending on the future growth rate expectations of investors.